.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Julphar
Chubb
Moodys
QuintilesIMS
Novartis
Cerilliant
Federal Trade Commission
Dow
Mallinckrodt

Generated: June 28, 2017

DrugPatentWatch Database Preview

TRIGLIDE Drug Profile

« Back to Dashboard

Which patents cover Triglide, and what generic Triglide alternatives are available?

Triglide is a drug marketed by Skyepharma Ag and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in thirteen countries.

The generic ingredient in TRIGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

Summary for Tradename: TRIGLIDE

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list81
Patent Applications: see list5,553
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TRIGLIDE at DailyMed

Pharmacology for Tradename: TRIGLIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Skyepharma Ag
TRIGLIDE
fenofibrate
TABLET;ORAL021350-001May 7, 2005DISCNNoNo6,696,084► SubscribeYY ► Subscribe
Skyepharma Ag
TRIGLIDE
fenofibrate
TABLET;ORAL021350-002May 7, 2005BXRXYesYes6,696,084► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: TRIGLIDE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,534,088 Fibrate-statin combinations with reduced fed-fasted effects► Subscribe
8,703,202Coated tablets► Subscribe
8,586,094Coated tablets► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TRIGLIDE

Country Document Number Estimated Expiration
Canada2423335► Subscribe
Germany60129573► Subscribe
Austria522211► Subscribe
Germany60127457► Subscribe
Australia2003225285► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Accenture
US Department of Justice
QuintilesIMS
Teva
Covington
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot